Suppr超能文献

泛素-蛋白酶体系统(UPS)通路抑制剂作为CRBN和VHL介导的靶向蛋白降解工具化合物的功能表征

Functional Characterization of Pathway Inhibitors for the Ubiquitin-Proteasome System (UPS) as Tool Compounds for CRBN and VHL-Mediated Targeted Protein Degradation.

作者信息

Schwalm Martin P, Menge Amelie, Elson Lewis, Greco Francesco A, Robers Matthew B, Müller Susanne, Knapp Stefan

机构信息

Institut für Pharmazeutische Chemie, Goethe-University Frankfurt, Biozentrum, Max-von-Laue-Str. 9, 60438 Frankfurt am Main, Germany.

Structural Genomics Consortium, Goethe-University Frankfurt, Buchmann Institute for Life Sciences, Max-von-Laue-Str. 15, 60438 Frankfurt am Main, Germany.

出版信息

ACS Chem Biol. 2025 Jan 17;20(1):94-104. doi: 10.1021/acschembio.4c00450. Epub 2025 Jan 3.

Abstract

Small molecule degraders such as PROteolysis TArgeting Chimeras (PROTACs) and molecular glues are new modalities for drug development and important tools for target validation. When appropriately optimized, both modalities lead to proteasomal degradation of the protein of interest (POI). Due to the complexity of the induced multistep degradation process, controls for degrader evaluation are critical and commonly used in the literature. However, comparative studies and evaluations of cellular potencies of these control compounds have not been published so far. Here, we investigated a diverse set of ubiquitin pathway inhibitors and evaluated their potency and utility within the CRBN and VHL-mediated degradation pathway. We used the HiBiT system to measure the level of target rescue after treatment with the control compounds. In addition, the cell health was assessed using a multiplexed high-content assay. These assays allowed us to determine nontoxic effective concentrations for control experiments and to perform rescue experiments in the absence of cellular toxicity.

摘要

小分子降解剂,如蛋白酶靶向嵌合体(PROTACs)和分子胶,是药物开发的新形式,也是靶点验证的重要工具。经过适当优化后,这两种形式都会导致目标蛋白(POI)的蛋白酶体降解。由于诱导的多步降解过程的复杂性,降解剂评估的对照至关重要,并且在文献中普遍使用。然而,到目前为止,尚未发表这些对照化合物细胞活性的比较研究和评估。在这里,我们研究了多种泛素途径抑制剂,并评估了它们在CRBN和VHL介导的降解途径中的活性和效用。我们使用HiBiT系统来测量用对照化合物处理后的靶点挽救水平。此外,使用多重高内涵分析评估细胞健康状况。这些分析使我们能够确定对照实验的无毒有效浓度,并在无细胞毒性的情况下进行挽救实验。

相似文献

2
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
SLAS Discov. 2021 Apr;26(4):484-502. doi: 10.1177/2472555220965528. Epub 2020 Nov 3.
4
Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs.
Bioorg Med Chem. 2019 Jun 15;27(12):2466-2479. doi: 10.1016/j.bmc.2019.02.048. Epub 2019 Feb 22.
7
Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
J Med Chem. 2020 Dec 24;63(24):15883-15905. doi: 10.1021/acs.jmedchem.0c01609. Epub 2020 Dec 7.
8
Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders.
Eur J Med Chem. 2024 Feb 5;265:116041. doi: 10.1016/j.ejmech.2023.116041. Epub 2023 Dec 14.
9
CRBN-PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical Applications.
Chem Biol Drug Des. 2024 Nov;104(5):e70009. doi: 10.1111/cbdd.70009.
10
Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
ACS Chem Biol. 2019 Oct 18;14(10):2215-2223. doi: 10.1021/acschembio.9b00525. Epub 2019 Oct 8.

引用本文的文献

1
Workflow for E3 Ligase Ligand Validation for PROTAC Development.
ACS Chem Biol. 2025 Feb 21;20(2):507-521. doi: 10.1021/acschembio.4c00812. Epub 2025 Feb 11.

本文引用的文献

1
Luciferase- and HaloTag-based reporter assays to measure small-molecule-induced degradation pathway in living cells.
Nat Protoc. 2024 Aug;19(8):2317-2357. doi: 10.1038/s41596-024-00979-z. Epub 2024 Apr 18.
2
Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes.
J Med Chem. 2023 Jul 27;66(14):9297-9312. doi: 10.1021/acs.jmedchem.3c00550. Epub 2023 Jul 5.
3
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization.
Cell Chem Biol. 2023 Jul 20;30(7):753-765.e8. doi: 10.1016/j.chembiol.2023.06.002. Epub 2023 Jun 23.
4
High-content live-cell multiplex screen for chemogenomic compound annotation based on nuclear morphology.
STAR Protoc. 2022 Oct 26;3(4):101791. doi: 10.1016/j.xpro.2022.101791. eCollection 2022 Dec 16.
5
Ubiquitin proteasome system in immune regulation and therapeutics.
Curr Opin Pharmacol. 2022 Dec;67:102310. doi: 10.1016/j.coph.2022.102310. Epub 2022 Oct 23.
6
PROTAC degraders as chemical probes for studying target biology and target validation.
Chem Soc Rev. 2022 Sep 20;51(18):7971-7993. doi: 10.1039/d2cs00478j.
7
PROTACs: past, present and future.
Chem Soc Rev. 2022 Jun 20;51(12):5214-5236. doi: 10.1039/d2cs00193d.
8
Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
Bioorg Med Chem Lett. 2022 May 15;64:128636. doi: 10.1016/j.bmcl.2022.128636. Epub 2022 Feb 26.
9
Image-Based Annotation of Chemogenomic Libraries for Phenotypic Screening.
Molecules. 2022 Feb 21;27(4):1439. doi: 10.3390/molecules27041439.
10
PROTAC targeted protein degraders: the past is prologue.
Nat Rev Drug Discov. 2022 Mar;21(3):181-200. doi: 10.1038/s41573-021-00371-6. Epub 2022 Jan 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验